Metagenics Acquires UK Probiotic Leader Symprove

Metagenics, the practitioner-focused nutritional supplement company backed by Gryphon Investors, has acquired Symprove, a clinically-studied liquid probiotic brand based in the United Kingdom. The transaction, announced February 11, 2025, marks a significant expansion of Metagenics' gut health portfolio and underscores the continued consolidation within the rapidly growing probiotics market.

Financial terms of the deal were not disclosed, though industry sources suggest the transaction values Symprove at a premium multiple reflective of its clinical differentiation and strong brand equity in the competitive gut health category. The acquisition represents a classic platform expansion strategy, with Gryphon-backed Metagenics leveraging its distribution infrastructure and practitioner network to accelerate Symprove's growth trajectory.

For Metagenics, the acquisition addresses a notable gap in its product portfolio. While the Aliso Viejo, California-based company has built a substantial business in vitamins, minerals, and specialty nutritional formulations distributed through healthcare practitioners, it has lacked a flagship probiotic offering with the clinical validation and consumer recognition that Symprove brings.

"Symprove's unique water-based delivery system and robust clinical evidence base make it an ideal complement to our existing product portfolio," said Alain Soucy, CEO of Metagenics, in the announcement. "This acquisition accelerates our strategy to become the leading provider of science-backed solutions across the full spectrum of functional wellness."

Founded in 2002 by Barry Smith—whose personal struggle with gut health issues inspired the development of the product—Symprove has distinguished itself in a crowded probiotics market through its proprietary liquid formulation. Unlike traditional capsule-based probiotics, Symprove's water-based delivery system is designed to bypass stomach acid more effectively, delivering live bacteria directly to the gut. The company has invested substantially in clinical research, with peer-reviewed studies published in journals examining its efficacy in conditions ranging from irritable bowel syndrome to inflammatory bowel disease.

The timing of this acquisition aligns with explosive growth in the global probiotics market. According to market research firm Grand View Research, the worldwide probiotics market was valued at approximately $61.1 billion in 2023 and is projected to expand at a compound annual growth rate of 8.3% through 2030, reaching nearly $105 billion by decade's end.

Several macroeconomic and scientific trends are driving this growth trajectory. Consumer awareness of the gut microbiome's role in overall health has increased dramatically, fueled by mainstream media coverage of gut-brain axis research and the microbiome's connection to immune function, mental health, and metabolic disorders. The COVID-19 pandemic further accelerated consumer interest in immune-supporting supplements, with probiotics benefiting from the broader wellness trend.

From an investment perspective, the probiotics category offers attractive characteristics: high margins, recurring revenue potential through subscription models, relatively low capital intensity, and significant white space for innovation. These dynamics have made the sector a magnet for private equity capital, with firms seeking to consolidate fragmented markets and build scaled platforms capable of supporting innovation and expanded distribution.

Gryphon Investors, a San Francisco-based middle-market private equity firm managing approximately $6 billion in assets, acquired Metagenics in 2021 from Alticor in a transaction reportedly valued north of $1 billion. Since taking ownership, Gryphon has pursued an aggressive platform expansion strategy, making multiple tuck-in acquisitions to broaden Metagenics' product portfolio and market reach.

The Symprove acquisition follows this established playbook. By adding a differentiated probiotic brand with strong clinical credentials and an established customer base, Gryphon is positioning Metagenics to capture incremental share in one of functional nutrition's fastest-growing subcategories. The deal also provides geographic diversification, with Symprove bringing significant presence in the UK and European markets where Metagenics has historically had lighter penetration.

The acquisition also reflects Gryphon's sector expertise. The firm has a track record in the health and wellness space, having previously invested in companies including Protocol Education, a healthcare services training provider, and Reliant Rehabilitation, a physical therapy platform. This sector focus allows Gryphon to leverage cross-portfolio insights and relationships to drive value creation.

The integration of Symprove into Metagenics' operations will likely focus on several key value creation levers. First, Metagenics' established relationships with functional medicine practitioners, nutritionists, and naturopathic physicians provide an immediate channel expansion opportunity for Symprove. While the UK brand has built its business primarily through direct-to-consumer channels and select retail partnerships, the practitioner channel represents significant untapped potential.

Second, Metagenics' operational infrastructure—including supply chain capabilities, quality assurance systems, and regulatory expertise—should allow Symprove to scale more efficiently. For a mid-sized brand like Symprove, access to these resources can meaningfully improve unit economics while maintaining product quality and compliance.

Third, there are likely opportunities to leverage Symprove's clinical research capabilities across Metagenics' broader portfolio. The parent company has historically emphasized evidence-based formulations, and Symprove's track record of publishing peer-reviewed research aligns well with this positioning. Cross-pollination of R&D expertise could accelerate innovation cycles and strengthen the combined entity's competitive moat.

The probiotics market remains highly fragmented despite the presence of several large players. Procter & Gamble's Align brand, Bayer's Phillips' Colon Health, Chr. Hansen's ingredient business, and numerous venture-backed startups like Seed Health and Pendulum all compete for consumer attention and practitioner recommendation.

What distinguishes winning brands in this environment is typically some combination of clinical differentiation, compelling consumer education, and effective distribution. Symprove has built meaningful equity in all three areas, particularly in the UK market where it has become synonymous with premium liquid probiotics. The challenge—and opportunity—for Metagenics will be replicating this success in North American markets while preserving the brand's premium positioning and clinical credibility.

While deal terms remain confidential, the transaction structure likely reflects current market conditions for middle-market M&A. With the Federal Reserve having cut interest rates modestly from their 2023 peaks but still maintaining a relatively restrictive stance, debt financing for middle-market transactions remains available though at higher costs than the zero-rate environment of 2020-2021.

For Gryphon, the acquisition represents a straightforward value-creation opportunity through operational improvement and revenue synergies. The firm's typical hold period of four to seven years suggests an exit timeline in the 2025-2028 window, potentially positioning the enhanced Metagenics platform for sale to a larger strategic acquirer or a secondary buyout to a larger private equity firm.

Logical strategic acquirers for a scaled nutritional supplements platform could include Nestlé Health Science, Church & Dwight, or Reckitt Benckiser, all of which have demonstrated appetite for premium wellness brands with strong clinical positioning. Alternatively, the company could pursue an IPO if public market receptivity to consumer health businesses improves from current levels.

The probiotics category exists in a complex regulatory environment, particularly in the United States where the FDA regulates such products as dietary supplements rather than pharmaceuticals. This classification allows for relatively faster market entry but imposes restrictions on health claims and requires careful navigation of allowable marketing language.

Symprove's strength in clinical research should serve the combined entity well in this environment. The brand has published studies in peer-reviewed journals including Alimentary Pharmacology & Therapeutics, providing evidence that can be referenced in practitioner education even if direct consumer marketing claims remain constrained. This evidence base also provides a measure of competitive protection, as replicating robust clinical validation requires substantial time and investment.

The scientific community's understanding of the microbiome continues to evolve rapidly, presenting both opportunities and risks. New research could validate additional use cases for probiotic supplementation—expanding addressable markets—or alternatively could reveal limitations of current probiotic strains or delivery methods. For investors, this scientific uncertainty underscores the importance of maintaining product development capabilities and staying current with emerging research.

The Metagenics-Symprove combination reflects broader themes in private equity's approach to the consumer health sector. Rather than simply cutting costs or implementing financial engineering, sophisticated sponsors are increasingly focused on building differentiated platforms through strategic M&A, operational improvement, and commercial transformation.

For Metagenics, success will be measured by the ability to accelerate Symprove's growth while maintaining its brand integrity and clinical reputation. Key performance indicators will likely include practitioner adoption rates in North America, subscription customer retention, and the ability to expand into adjacent product categories leveraging the Symprove brand equity.

For the broader market, this transaction serves as another data point in the ongoing consolidation of the nutritional supplements industry. As consumers become more sophisticated and demand greater scientific validation, brands with credible clinical evidence and differentiated delivery mechanisms should command premium valuations. Private equity's willingness to deploy capital behind these attributes suggests continued M&A activity in the sector throughout 2025 and beyond.

The gut health category specifically appears positioned for sustained growth, supported by continued scientific discoveries linking the microbiome to diverse health outcomes and increasing mainstream acceptance of probiotics as a foundational wellness tool. For Gryphon Investors and Metagenics, the Symprove acquisition represents a strategic bet on these long-term trends—a bet that, if executed well, could generate substantial returns while advancing the state of evidence-based nutritional medicine.

For thumbnail imagery, consider these search queries:

• "probiotic supplement liquid bottle laboratory"• "gut health microbiome scientific research"• "nutritional supplement clinical testing professional"• "wellness brand bottles clean aesthetic healthcare"• "bacterial culture laboratory microscope probiotics"